Phosphodiesterases

Abstract

The invention provides human phosphodiesterases (HPDE) and polynucleotides which identify and encode HPDE. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of HPDE.

1 - 28 . (canceled)  
     
     
         29 . An isolated polypeptide selected from the group consisting of: 
 (a) a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 3;    (b) a polypeptide comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 3;    (c) a biologically active fragment of a polypeptide having the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 3; and    (d) an immunogenic fragment of a polypeptide having the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 3.    
     
     
         30 . An isolated polypeptide of  claim 29  selected from the group consisting of SEQ ID NO: 2 or SEQ ID NO: 3.  
     
     
         31 . An isolated polynucleotide encoding the polypeptide of  claim 29 .  
     
     
         32 . An isolated polynucleotide encoding the polypeptide of  claim 30 .  
     
     
         33 . An isolated polynucleotide of  claim 32  selected from the group consisting of SEQ ID NO: 5 or SEQ ID NO: 6.  
     
     
         34 . A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of  claim 31 .  
     
     
         35 . A cell transformed with a recombinant polynucleotide of  claim 34 .  
     
     
         36 . A composition comprising the polypeptide of  claim 29  in conjunction with a suitable pharmaceutical carrier.  
     
     
         37 . A method for producing a polypeptide of  claim 29 , the method comprising: 
 culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding a polypeptide of  claim 29 , and recovering the polypeptide so expressed.    
     
     
         38 . An isolated polynucleotide selected from the group consisting of: 
 (a) a polynucleotide comprising the polynucleotide sequence of SEQ ID NO: 5 or SEQ ID NO: 6;    (b) a polynucleotide comprising a polynucleotide sequence at least 90% identical to the polynucleotide sequence of SEQ ID NO: 5 or SEQ ID NO: 6;    (c) a polynucleotide complementary to the polynucleotide of (a);    (d) a polynucleotide complementary to the polynucleotide of (b); and    (e) an RNA equivalent of (a)-(d).    
     
     
         39 . A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of  claim 38 , the method comprising: 
 hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof; and    detecting the presence or absence of said hybridization complex and, optionally, if present, the amount thereof.    
     
     
         40 . A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of  claim 38 , the method comprising: 
 amplifying said target polynucleotide or fragment thereof using polymerase chain reaction; and    detecting the presence or absence of said target polynucleotide and, optionally, if present, the amount thereof.    
     
     
         41 . An isolated antibody which specifically binds to a polypeptide of  claim 29 .  
     
     
         42 . A method for treating or preventing a disorder associated with aberrant expression of HPDE, the method comprising administering to a subject in need of such treatment an effective amount of the composition of  claim 36 .  
     
     
         43 . The isolated polypeptide of  claim 29 , wherein said polypeptide comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 3.  
     
     
         44 . The isolated polynucleotide of  claim 38 , wherein said polynucleotide comprises a polynucleotide sequence at least 95% identical to the polynucleotide sequence of SEQ ID NO: 4 or SEQ ID NO: 5.